Pasithea Therapeutics (KTTA) Competitors $0.70 -0.03 (-3.71%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$0.69 -0.01 (-1.03%) As of 08/1/2025 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock KTTA vs. NAII, CMMB, RLMD, ASBP, FNCH, BCAB, SYBX, RLYB, RVPH, and LEXXShould you be buying Pasithea Therapeutics stock or one of its competitors? The main competitors of Pasithea Therapeutics include Natural Alternatives International (NAII), Chemomab Therapeutics (CMMB), Relmada Therapeutics (RLMD), Aspire Biopharma (ASBP), Finch Therapeutics Group (FNCH), BioAtla (BCAB), Synlogic (SYBX), Rallybio (RLYB), Reviva Pharmaceuticals (RVPH), and Lexaria Bioscience (LEXX). These companies are all part of the "pharmaceutical products" industry. Pasithea Therapeutics vs. Its Competitors Natural Alternatives International Chemomab Therapeutics Relmada Therapeutics Aspire Biopharma Finch Therapeutics Group BioAtla Synlogic Rallybio Reviva Pharmaceuticals Lexaria Bioscience Natural Alternatives International (NASDAQ:NAII) and Pasithea Therapeutics (NASDAQ:KTTA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, institutional ownership, earnings, risk, valuation, dividends and analyst recommendations. Which has more risk and volatility, NAII or KTTA? Natural Alternatives International has a beta of 0.64, meaning that its stock price is 36% less volatile than the S&P 500. Comparatively, Pasithea Therapeutics has a beta of 0.25, meaning that its stock price is 75% less volatile than the S&P 500. Which has preferable earnings and valuation, NAII or KTTA? Natural Alternatives International has higher revenue and earnings than Pasithea Therapeutics. Natural Alternatives International is trading at a lower price-to-earnings ratio than Pasithea Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNatural Alternatives International$125.48M0.18-$7.22M-$1.39-2.69Pasithea TherapeuticsN/AN/A-$13.90M-$10.60-0.07 Is NAII or KTTA more profitable? Pasithea Therapeutics has a net margin of 0.00% compared to Natural Alternatives International's net margin of -6.56%. Natural Alternatives International's return on equity of -10.34% beat Pasithea Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Natural Alternatives International-6.56% -10.34% -5.19% Pasithea Therapeutics N/A -88.14%-81.21% Do institutionals & insiders believe in NAII or KTTA? 32.4% of Natural Alternatives International shares are held by institutional investors. Comparatively, 23.9% of Pasithea Therapeutics shares are held by institutional investors. 20.9% of Natural Alternatives International shares are held by company insiders. Comparatively, 2.7% of Pasithea Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Does the media favor NAII or KTTA? In the previous week, Pasithea Therapeutics had 2 more articles in the media than Natural Alternatives International. MarketBeat recorded 2 mentions for Pasithea Therapeutics and 0 mentions for Natural Alternatives International. Natural Alternatives International's average media sentiment score of 0.00 equaled Pasithea Therapeutics'average media sentiment score. Company Overall Sentiment Natural Alternatives International Neutral Pasithea Therapeutics Neutral SummaryNatural Alternatives International beats Pasithea Therapeutics on 8 of the 11 factors compared between the two stocks. Get Pasithea Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KTTA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KTTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KTTA vs. The Competition Export to ExcelMetricPasithea TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.40M$3.00B$5.48B$9.51BDividend YieldN/A2.43%4.73%4.09%P/E Ratio-0.0717.6228.6723.80Price / SalesN/A179.18373.9066.58Price / CashN/A41.9535.4557.96Price / Book0.078.508.275.55Net Income-$13.90M-$55.06M$3.24B$259.03M7 Day Performance-3.83%-3.98%-3.69%-4.59%1 Month Performance-6.63%9.59%4.33%4.46%1 Year Performance-85.75%6.72%25.95%18.03% Pasithea Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KTTAPasithea Therapeutics0.699 of 5 stars$0.70-3.7%N/A-86.1%$5.40MN/A-0.073News CoverageNAIINatural Alternatives InternationalN/A$3.47+3.3%N/A-34.6%$20.76M$113.80M-2.50290CMMBChemomab Therapeutics2.9335 of 5 stars$1.12+1.8%$8.50+658.9%-11.6%$20.74MN/A-1.4720Positive NewsRLMDRelmada Therapeutics4.4542 of 5 stars$0.63+1.9%$5.00+699.4%-84.0%$20.38MN/A-0.2510News CoverageUpcoming EarningsASBPAspire BiopharmaN/A$0.39-4.5%N/AN/A$20.24MN/A0.00N/AFNCHFinch Therapeutics GroupN/A$12.39+0.8%N/A+556.3%$19.90MN/A-1.40190BCABBioAtla2.0695 of 5 stars$0.34+1.6%$5.00+1,365.0%-81.1%$19.63M$11M-0.2860Upcoming EarningsSYBXSynlogic1.0261 of 5 stars$1.60-4.4%N/A-14.0%$19.58M$10K-0.6480Upcoming EarningsHigh Trading VolumeRLYBRallybio1.9583 of 5 stars$0.49+5.6%$10.00+1,947.9%-59.5%$19.24M$640K-0.4540Negative NewsShort Interest ↑RVPHReviva Pharmaceuticals2.8464 of 5 stars$0.41+3.9%$9.00+2,091.4%-59.3%$18.98MN/A-0.525Short Interest ↑LEXXLexaria Bioscience2.7019 of 5 stars$0.97+1.6%$5.00+415.5%-78.6%$18.67M$460K-1.457News CoverageAnalyst ForecastAnalyst RevisionGap Down Related Companies and Tools Related Companies Natural Alternatives International Alternatives Chemomab Therapeutics Alternatives Relmada Therapeutics Alternatives Aspire Biopharma Alternatives Finch Therapeutics Group Alternatives BioAtla Alternatives Synlogic Alternatives Rallybio Alternatives Reviva Pharmaceuticals Alternatives Lexaria Bioscience Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KTTA) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pasithea Therapeutics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pasithea Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
